A numerical framework for simulating fluid-structure interaction phenomena

In this paper, a numerical tool able to solve fluid-structure interaction problems is proposed. The lattice Boltzmann method is used to compute fluid dynamics, while the corotational finite element formulation together with the Time Discontinuous Galerkin method are adopted to predict structure dynamics. The Immersed Boundary method is used to account for the presence of an immersed solid in the lattice fluidbackground and to handle fluid-structure interface conditions, while a Volume-of-Fluid-based method isadopted to take trace of the evolution of the free surface. These ingredients are combined through a partitioned staggered explicit strategy, according to an efficient and accurate algorithm recently developed by the authors. The effectiveness of the proposed methodology is tested against two different cases. The former investigates the dam break phenomenon, involving the modeling of the free surface. The latter involves the vibration regime experienced by two highly deformable flapping flags obstructing a flow. A wide numerical campaign is carried out by computing the error in terms of interface energy artificially introduced at the fluid-solid interface. Moreover, the structure behavior is dissected by simulating scenarios characterized by different values of the Reynolds number. Present findings are compared to literature results, showing a very close agreement.&nbsp

A numerical framework for simulating fluid-structure interaction phenomena

In this paper, a numerical tool able to solve fluid-structure interaction problems is proposed. The lattice Boltzmann method is used to compute fluid dynamics, while the corotational finite element formulation together with the Time Discontinuous Galerkin method are adopted to predict structure dynamics. The Immersed Boundary method is used to account for the presence of an immersed solid in the lattice fluid background and to handle fluid-structure interface conditions, while a Volume-of-Fluid-based method is adopted to take trace of the evolution of the free surface. These ingredients are combined through a partitioned staggered explicit strategy, according to an efficient and accurate algorithm recently developed by the authors. The effectiveness of the proposed methodology is tested against two different cases. The former investigates the dam break phenomenon, involving the modeling of the free surface. The latter involves the vibration regime experienced by two highly deformable flapping flags obstructing a flow. A wide numerical campaign is carried out by computing the error in terms of interface energy artificially introduced at the fluid-solid interface. Moreover, the structure behavior is dissected by simulating scenarios characterized by different values of the Reynolds number. Present findings are compared to literature results, showing a very close agreement

lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing

n/

Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy

Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive biomarkers in non-small cell lung cancer (NSCLC). In this study, we examined the prognostic role of cfDNA and CTCs, in separate and joint analyses, in NSCLC patients receiving first line chemotherapy. Seventy-three patients with advanced NSCLC were enrolled in this study. CfDNA and CTC were analyzed at baseline and after two cycles of chemotherapy. Plasma cfDNA quantification was performed by quantitative PCR (qPCR) whereas CTCs were isolated by the ScreenCell Cyto (ScreenCell, Paris, France) device and enumerated according to malignant features. Patients with baseline cfDNA higher than the median value (96.3 hTERT copy number) had a significantly worse overall survival (OS) and double the risk of death (hazard ratio (HR): 2.14; 95% confidence limits (CL) = 1.24\u20133.68; p-value = 0.006). Conversely, an inverse relationship between CTC median baseline number (6 CTC/3 mL of blood) and OS was observed. In addition, we found that in patients reporting stable disease (SD), the baseline cfDNA and CTCs were able to discriminate patients at high risk of poor survival. cfDNA demonstrated a more reliable biomarker than CTCs in the overall population. In the subgroup of SD patients, both biomarkers identified patients at high risk of poor prognosis who might deserve additional/alternative therapeutic interventions

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) refractory to standard therapies have a poor prognosis. In this setting, recruitment into clinical trials is warranted, and studies driven by selection according to individual tumor molecular characteristics are expected to provide added value. OBJECTIVE: We retrospectively analyzed data from patients with mCRC refractory to or following failure of standard therapies who were enrolled into phase I/II clinical studies at the Niguarda Cancer Center based on the presence of a specific molecular profile expected to represent the target of susceptibility to the experimental drug(s). PATIENTS AND METHODS: From June 2011 to May 2016, 2044 patients with mCRC underwent molecular screening. Eighty patients (3.9%) were enrolled in ad hoc studies; the median age was 60 years (range 36-86) and the median number of previous treatment lines was five (range 2-8). Molecular characteristics exploited within these studies were MGMT promoter hypermethylation (48.7%), HER2 amplification (28.8%), BRAF V600E mutation (20%), and novel gene fusions involving ALK or NTRK (2.5%). RESULTS: One patient (1%) had RECIST (Response Evaluation Criteria In Solid Tumors) complete response (CR), 13 patients (16.5%) experienced a partial response (PR), and 28 (35%) stable disease (SD). Median progression-free survival (PFS) was 2.8 months (range 2.63-3.83), with 24% of patients displaying PFS >5 months. Median growth modulation index (GMI) was 0.85 (range 0-15.61) and 32.5% of patients had GMI >1.33. KRAS exon 2 mutations were found in 38.5% of patients, and among the 78 patients with known KRAS status, those with wild-type tumors had longer PFS than those with mutated tumors (3.80 [95% CI 2.80-5.03] vs. 2.13 months [95% CI 1.77-2.87], respectively, p = 0.001). Median overall survival (OS) was 7.83 months (range 7.17-9.33) for all patients, and patients with KRAS wild-type tumors had longer OS than those with mutated tumors (7.83 [95% CI 7.33-10.80] vs. 7.18 months [95% CI 5.63-9.33], respectively, p = 0.06). CONCLUSIONS: This single-institution retrospective study indicates that in a heavily pretreated population approximately 4% of mCRC tumors display a potential actionable molecular context suitable for therapeutic intervention. Application of molecular selection is challenging but improves clinical outcome even in later lines of treatment

Pore-scale mechanism for selective permeability reduction by polymer injection

In this paper we discuss a pore-scale picture of the mechanism underlying the selective permeability reduction caused by the adsorption of a polymer layer in a water wet porous medium. Our analysis is based on the use of physically representative model of the porous medium, which allows us to estimate directly the expected permeability reduction. Comparison of model predictions with coreflood experimental data has revealed that the selectivity in permeability reduction cannot be explained if the polymer layer is modeled as a rigid, impenetrable layer. This result is consistent with the suggestion that swelling-shrinking phenomena of the adsorbed polymer later is responsible for the selectivity in the permeability modification induced by these treatments